-
公开(公告)号：US20190030183A1
公开(公告)日：2019-01-31
申请号：US15748268
申请日：2016-08-09
Applicant: PFIZER INC.
Inventor： Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
Patent Agency Ranking
公开(公告)号：US20150322135A1
公开(公告)日：2015-11-12
申请号：US14650188
申请日：2013-11-25
Applicant: PFIZER INC.
Inventor： Tetsuya Ishino , Weili Duan , Ronald William Kriz
IPC: C07K16/00
CPC classification number: C07K16/00 , C07K2299/00 , C07K2317/41 , C07K2317/524 , C07K2317/526 , C07K2317/55 , C07K2317/64 , C07K2317/94
Abstract: The present invention relates to monomeric polypeptides comprising an engineered monomeric antibody fragment (e.g., monomeric Fc-containing polypeptides) wherein the monomeric Fc comprises one or more engineered N-linked glycosylation sites in the CH3-CH3 dimerization interface. Methods for producing such engineered monomeric antibody fragments and their use in diagnostics and therapeutics are also provided.
Abstract translation: 本发明涉及包含工程化单体抗体片段（例如含单体Fc的多肽）的单体多肽，其中单体Fc包含在CH3-CH3二聚化界面中的一个或多个工程化的N-连接的糖基化位点。 还提供了生产这种工程化单体抗体片段的方法及其在诊断和治疗中的应用。
-
公开(公告)号：US20200230256A1
公开(公告)日：2020-07-23
申请号：US16807375
申请日：2020-03-03
Applicant: PFIZER INC.
Inventor： Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
公开(公告)号：US10653794B2
公开(公告)日：2020-05-19
申请号：US15748268
申请日：2016-08-09
Applicant: PFIZER INC.
Inventor： Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
公开(公告)号：US10233229B2
公开(公告)日：2019-03-19
申请号：US14650188
申请日：2013-11-25
Applicant: Pfizer Inc.
Inventor： Tetsuya Ishino , Weili Duan , Ronald William Kriz
Abstract: The present invention relates to monomeric polypeptides comprising an engineered monomeric antibody fragment (e.g., monomeric Fc-containing polypeptides) wherein the monomeric Fc comprises one or more engineered N-linked glycosylation sites in the CH3-CH3 dimerization interface. Methods for producing such engineered monomeric antibody fragments and their use in diagnostics and therapeutics are also provided.
-
公开(公告)号：US11980669B2
公开(公告)日：2024-05-14
申请号：US16807375
申请日：2020-03-03
Applicant: PFIZER INC.
Inventor： Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
CPC classification number: A61K47/6889 , A61K38/05 , A61K47/68 , A61K47/6817 , A61K47/6851 , A61K47/6855 , C07K16/00 , C07K16/30 , C07K2317/14 , C07K2317/40 , C07K2317/526 , C07K2317/55 , C07K2317/94
Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
-
-
-
-
Search Results
6
records
(took 0.014 seconds)
